Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Updated consensus recommendations cover first and subsequent lines of treatment as well emerging options such as novel BTK inhibitors and BCL2 antagonist venetoclax, noting choice of therapy should be guided by patient's clinical profile, genomic features, and drug availability.

Source:

The Lancet Haematology